The strategic alternatives review is the primary catalyst — a sale or merger could unlock value above the $23M market cap, but there is no timeline and the process could yield nothing. Monitor for any 8-K disclosing a definitive agreement or termination of the process. The royalty business generates modest but growing cash flow, reducing near-term distress risk.
Price Chart
Executive Summary
TherapeuticsMD reported Q1 2026 results: net income from continuing operations of $103K vs a net loss of $636K in Q1 2025, and license revenue of $724K, up 84% YoY from $393K. The company continues to evaluate strategic alternatives including a potential sale or merger, but has no timetable or assurance of a deal. With a $23M market cap and $8.4M cash, the business is small and the strategic review process creates binary event risk.
Key Facts
- Net income from continuing operations of $103K vs net loss of $636K in Q1 2025
- License revenue of $724K, up 84% from $393K in Q1 2025
- Total operating expenses decreased 13.6% to $1.447M from $1.674M
- Cash and cash equivalents of $8.4M as of March 31, 2026
- Company continues to evaluate strategic alternatives including acquisition, merger, or sale of assets
- No timetable or assurance of any strategic transaction outcome
Financial Impact
Net income swing of +$739K YoY; license revenue increase of $331K; cash burn minimal at ~$0.5M/quarter
Risk Factors
- Strategic alternatives process may not result in any transaction
- Dependence on Mayne Pharma license for virtually all revenue
- Nasdaq listing compliance risk (noted in forward-looking statements)
- Micro-cap with limited liquidity — binary event risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-055070 |
| Document: ea028977601ex99-1.htm | 0001213900-26-055070 |
| Document: 0001213900-26-055070-index-headers.html | 0001213900-26-055070 |
| Document: 0001213900-26-055070-index.html | 0001213900-26-055070 |
| Document: 0001213900-26-055070.txt | 0001213900-26-055070 |
| 8-K Data (Synthetic) | 0001213900-26-055070 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $2.08 $2.10 | ▼ −0.96% | ▼ −2.86% | $1.80 (+13.46%) |
May 12, 2026 23w ago | 8-K | $2.02 $1.82 | ▼ −9.90% | ▼ −9.29% | $1.80 (−10.89%) |
Mar 31, 2026 29w ago | 10-K/A | $2.00 $2.11 | ▼ −5.50% | ▲ +4.22% | $1.80 (+10.00%) |
Mar 30, 2026 30w ago | 8-K | $2.02 $2.10 | ▲ +3.96% | ▼ −5.46% | $1.80 (−10.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers